Concentrations of the DNA methyltransferase inhibitor 5-fluoro-2′-deoxycytidine (FdCyd) and its cytotoxic metabolites in plasma of patients treated with FdCyd and tetrahydrouridine (THU)

被引：0
|
作者：
Jan H. Beumer
Robert A. Parise
Edward M. Newman
James H. Doroshow
Timothy W. Synold
Heinz-Josef Lenz
Merrill J. Egorin
机构：
[1] University of Pittsburgh Cancer Institute,Molecular Therapeutics/Drug Discovery Program
[2] University of Pittsburgh,Department of Pharmaceutical Sciences, School of Pharmacy
[3] Beckman Research Institute of the City of Hope,Division of Molecular Medicine
[4] City of Hope National Medical Center,Division of Medical Oncology and Therapeutics Research
[5] National Cancer Institute,Division of Cancer Treatment and Diagnosis
[6] University of Southern California,Norris Cancer Center
[7] University of Pittsburgh,Department of Medicine, School of Medicine
[8] University of Pittsburgh,Department of Pharmacology, School of Medicine
[9] University of Pittsburgh Cancer Institute,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2008年 / 62卷
关键词：
Metabolism; Pyrimidine; DNA methylation inhibitor; Phase I; Tetrahydrouridine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：363 / 368
页数：5
相关论文
共 18 条
  • [1] Concentrations of the DNA methyltransferase inhibitor 5-fluoro-2′-deoxycytidine (FdCyd) and its cytotoxic metabolites in plasma of patients treated with FdCyd and tetrahydrouridine (THU)
    Beumer, Jan H.
    Parise, Robert A.
    Newman, Edward M.
    Doroshow, James H.
    Synold, Timothy W.
    Lenz, Heinz-Josef
    Egorin, Merrill J.
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 62 (02) : 363 - 368
  • [2] Concentrations of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycyticine (FdCyd) & its metabolites 5-fluora-2'-deoxyuridine (FdUrd), 5-fluorouracil (FU), 5-fluorouridine (FUrd), & 5-fluorocytosine (FC) in plasma of patients treated with FdCyd.
    Beumer, J. H.
    Parise, R. A.
    Newman, E. M.
    Doroshow, J. . H.
    Synold, T. W.
    Lenz, H.
    Egorin, M. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 84S - 84S
  • [3] A phase I, pharmacokinetic, and pharmacodynamic evaluation of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine, administered with tetrahydrouridine
    Newman, Edward M.
    Morgan, Robert J.
    Kummar, Shivaani
    Beumer, Jan H.
    Blanchard, M. Suzette
    Ruel, Christopher
    El-Khoueiry, Anthony B.
    Carroll, Mary I.
    Hou, Jessie M.
    Li, Chun
    Lenz, Heinz J.
    Eiseman, Julie L.
    Doroshow, James H.
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (03) : 537 - 546
  • [4] A phase I, pharmacokinetic, and pharmacodynamic evaluation of the DNA methyltransferase inhibitor 5-fluoro-2′-deoxycytidine, administered with tetrahydrouridine
    Edward M. Newman
    Robert J. Morgan
    Shivaani Kummar
    Jan H. Beumer
    M. Suzette Blanchard
    Christopher Ruel
    Anthony B. El-Khoueiry
    Mary I. Carroll
    Jessie M. Hou
    Chun Li
    Heinz J. Lenz
    Julie L. Eiseman
    James H. Doroshow
    [J]. Cancer Chemotherapy and Pharmacology, 2015, 75 : 537 - 546
  • [5] Pharmacokinetics, metabolism, and oral bioavailability of the DNA methyltransferase inhibitor 5-fluoro-2′-deoxycytidine in mice
    Beumer, Jan H.
    Eiseman, Julie L.
    Parise, Robert A.
    Joseph, Erin
    Holleran, Julianne L.
    Covey, Joseph M.
    Egorin, Merrill J.
    [J]. CLINICAL CANCER RESEARCH, 2006, 12 (24) : 7483 - 7491
  • [6] Phase I and pharmacokinetic evaluation of the DNA methyltransferase inhibitor 5-fluoro-2′-deoxycytidine: A California Cancer Consortium study
    Newman, Edward M.
    Morgan, Robert J.
    Beumer, Jan H.
    Blanchard, Suzette M.
    EI-Khoueiry, Anthony B.
    Kummar, Shivaani
    Carroll, Mary I.
    Synold, Timothy W.
    Lenz, Heinz J.
    Doroshow, James H.
    [J]. CANCER RESEARCH, 2011, 71
  • [7] Phase I trial of oral 5-fluoro-2′-deoxycytidine with oral tetrahydrouridine in patients with advanced solid tumors
    Coyne, G. O'Sullivan
    Chen, A. P.
    Kummar, S.
    Meehan, R. S.
    Collins, J.
    Zlott, J.
    Kelly, K.
    Lenz, H. J.
    Newman, E. M.
    Morgan, R.
    Juwara, L.
    Eiseman, J.
    Beumer, J. H.
    Tomaszewski, J.
    Doroshow, J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2016, 69 : S90 - S90
  • [8] EFFECT OF 5-FLUORO-2'-DEOXYURIDINE (FDURD) AND TETRAHYDROURIDINE (THU) ON INHIBITION BY DEOXYCYTIDINE (DCYD) AND CYTIDINE (CYD) OF INDUCTION OF HELA ALKALINE-PHOSPHATASE (AP) ACTIVITY
    RYAN, R
    GOZ, B
    [J]. PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1980, 21 (MAR): : 268 - 268
  • [9] Inhibition of cancer cell proliferation by 5-fluoro-2′-deoxycytidine, a DNA methylation inhibitor, through activation of DNA damage response pathway
    Zhao, Quanyi
    Fan, Jiadong
    Hong, Wei
    Li, Lianyun
    Wu, Min
    [J]. SPRINGERPLUS, 2012, 1
  • [10] Intravenous 5-fluoro-2′-deoxycytidine administered with tetrahydrouridine increases the proportion of p16-expressing circulating tumor cells in patients with advanced solid tumors
    Geraldine O.’Sullivan Coyne
    Lihua Wang
    Jennifer Zlott
    Lamin Juwara
    Joseph M. Covey
    Jan H. Beumer
    Mihaela C. Cristea
    Edward M. Newman
    Stephen Koehler
    Jorge J. Nieva
    Agustin A. Garcia
    David R. Gandara
    Brandon Miller
    Sonny Khin
    Sarah B. Miller
    Seth M. Steinberg
    Larry Rubinstein
    Ralph E. Parchment
    Robert J. Kinders
    Richard L. Piekarz
    Shivaani Kummar
    Alice P. Chen
    James H. Doroshow
    [J]. Cancer Chemotherapy and Pharmacology, 2020, 85 : 979 - 993
12